Tideglusib protects neural stem cells against NMDA receptor overactivation. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Tideglusib prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders.
For research use only. We do not sell to patients.
| Name | Tideglusib |
|---|---|
| Iupac Chemical Name | 2-(1-naphthalenyl)-4-(phenylmethyl)-1,2,4-thiadiazolidine-3,5-dione |
| Synonyms | NP031112; NP 031112; NP-031112; Tideglusib. |
| Molecular Formula | C19H14N2O2S |
| Molecular Weight | 334.393 |
| Smile | C1(=CC=CC2=CC=CC=C12)N1SC(N(C1=O)CC1=CC=CC=C1)=O |
| InChiKey | PMJIHLSCWIDGMD-UHFFFAOYSA-N |
| InChi | InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2 |
| CAS Number | 865854-05-3 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% |
| Storage | -20 ºC for 3 years |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |